Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability. 

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Dexcel Pharma has acquired eight OTC brands from Teva, including Bisodol Indigestion Relief Tablets, erectile dysfunction treatment Liberize and Yeast Vite supplements. Teva told HBW Insight it remains committed to the consumer health market despite a number of recent brand divestments.

Futura Medical has extended its licensing agreement with Cooper Consumer Health for the rights to market its Eroxon topical, gel-based erectile dysfunction treatment throughout the European Economic Area, United Kingdom and Switzerland until 2029.